Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM1002 PK DDI Study with Rifampicin or Itraconazole
NCT06562088Phase 1Not yet recruiting
- Sponsor
- Huadong Medicine
- Start
- Aug 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of conveglipron in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Huadong Medicine. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity, Area Under the Concentration-Time Curve From Time Zero to 24 Hours and 6 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
conveglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06562088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06562088.